Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
-0.01 (-0.51%)
Oct 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.93 - 2.03
52 week 1.57 - 3.44
Open 2.00
Vol / Avg. 484,934.00/817,065.00
Mkt cap 270.16M
P/E     -
Div/yield     -
EPS -0.72
Shares 136.44M
Beta 1.91
Inst. own 22%
Sep 9, 2015
Synta Pharmaceuticals Corp at FBR Healthcare Conference
Aug 6, 2015
Q2 2015 Synta Pharmaceuticals Corp Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Synta Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -87.79% -87.97%
Return on average equity -137.97% -150.86%
Employees 110 -
CDP Score - -


United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company focuses on research, development and commercialization of oncology medicines for cancer patients. Its lead oncology drug candidate is ganetespib, which is a heat shock protein 90 (Hsp90) inhibitor. The Company also has an additional clinical-stage oncology candidate: elesclomol, which is a mitochondrial metabolism inhibitor. Ganetespib is a small molecule inhibitor of Hsp90, which is a molecular chaperone required for the folding and activation of cancer-promoting proteins. Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death (apoptosis) in cancer cells through a mechanism: disrupting cancer cell energy metabolism. The Company entered into a license arrangement for its calcium release-activated calcium channel (CRACM) program, including two candidates and the associated intellectual property portfolio, with PRCL Research Inc. (PRCL).

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Vojo Vukovic M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Robert N. Wilson Jr. Independent Director
Age: 74
Bio & Compensation  - Reuters